While existing IO treatments have focused on improving T-cell function through inhibition of PD-1 or CTLA-4, multiple other T-cell inhibitory pathways and the myeloid compartment play a significant role in the immune dysfunction in RCC and combination IO strategies that target multiple components of the TME are likely warranted. Here, CTLA4 is linked to renal cell carcinoma.